The World of Health & Medicine News

US to stop financial support of global vaccine alliance Gavi, health secretary says

US to stop financial support of global vaccine alliance Gavi, health secretary says

The U.S. will no longer contribute funding to Gavi, a global alliance that helps buy vaccines for the world’s poorest children, because it ignores safety, Health Secretary Robert F. Kennedy Jr. said on Wednesday, without providing evidence.

In a video statement seen by Reuters and shown at a Gavi fundraising event in Brussels, Kennedy – a long-time vaccine skeptic – also accused Gavi of making questionable recommendations around COVID-19 vaccines, and raised concerns about the DTPw (diphtheria-tetanus-whole cell pertussis) vaccine.

Gavi said in a statement that safety was key, and that it acts in line with World Health Organization recommendations. It has full confidence in the DTPw vaccine, which has contributed to halving child mortality in the countries it supports since 2000, the statement continued.

“I call on Gavi today to re-earn the public trust, and to justify the $8 billion that America has provided in funding since 2001,” Kennedy said in the video, saying Gavi should consider all available science.

“Until that happens, the United States won’t contribute more,” he said.

Gavi said it “fully concurs with the Secretary for Health and Human Services on the need to consider all available science, and remains committed to continuing an evidence-based and scientific approach to its work and investment decisions, as it always has done.”

Gavi leaders, donors and countries it works with are in Brussels for the organization’s pledging summit, where the alliance aims to raise $9 billion for its work from 2026-30.

Kennedy said in the video that he admired much of Gavi’s work, particularly its efforts to make medicines affordable worldwide.

“Unfortunately, in its zeal to promote universal vaccination, it has neglected the key issue of vaccine safety,” he added.

“Gavi’s utmost concern is the health and safety of children,” the group’s statement responded.

Several key figures also defended Gavi’s commitment to safety in speeches at the summit, including its board Chair Jose Manuel Barroso and Bill Gates, chair of the Gates Foundation, which is hosting the summit alongside the European Union.

“Gavi prioritizes saving lives, and it’s done with incredible scientific rigor,” said Gates. “We’re constantly looking at safety.”

The Trump administration has previously indicated that it planned to cut its funding for Gavi, around $300 million annually, as part of a wider pullback from international aid.

President Donald Trump’s nominee for director of the Centers for Disease Control and Prevention, Susan Monarez, was asked about the Gavi decision at a Senate hearing on Wednesday.

“I believe the global health security preparedness is a critical and vital activity for the United States,” she said.

“I think that we need to continue to support promotion of utilization of vaccines,” she continued, adding that she was not involved in that decision-making and would look into it if confirmed.

Other donors, including Germany, Norway, and the Gates Foundation, have already pledged money in recent days for Gavi’s future work.

spot_img

Explore more

spot_img

Scientists Warn: Long Work Hours May Physically Alter Your Brain

Scientists Warn: Long Work Hours May Physically Alter Your Brain Overwork can lead to neuroadaptive changes that impair cognitive and emotional health. Working long hours may...

China’s Sciwind’s GLP-1 shows similar weight loss to Novo’s Wegovy, study...

China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds Overweight patients given an experimental weight loss drug being developed by China's Sciwind...

Lilly to launch Mounjaro pen in India to compete with Novo’s...

Lilly to launch Mounjaro pen in India to compete with Novo's weight-loss drug Wegovy India's drug regulator on Thursday approved the launch of pre-filled injector...

Novo Nordisk’s experimental drug results in up to 24% weight loss

Novo Nordisk's experimental drug results in up to 24% weight loss Novo Nordisk on Friday said full results from early-stage trials show that its experimental...

Pfizer’s bleeding disorder therapy succeeds in trial with patients with certain...

Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in...

Nestle USA to phase out use of synthetic food colors by...

Nestle USA to phase out use of synthetic food colors by mid-2026 Nestle USA said on Wednesday that it would fully eliminate synthetic food colors...

Nektar’s lead drug candidate shows promise in eczema trial, shares soar

Nektar's lead drug candidate shows promise in eczema trial, shares soar  Nektar Therapeutics (NKTR.O), opens new tab said on Tuesday its lead drug candidate met the main...

US FDA approves Gilead’s twice-yearly injection for HIV prevention

US FDA approves Gilead's twice-yearly injection for HIV prevention The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences (GILD.O), opens new tab lenacapavir, a twice-yearly...